The biotech has chosen to close the Colorado offices following the $1.4bn (€1bn) acquisition of California-based CV Therapeutics. This created an overlap in expertise that Gilead is resolving by closing the Colorado offices.
Gilead hopes to relocate 73 of the 139 staff that work in the Colorado offices. The offices will close at the end of 2009 or in the first two weeks of next year.